Literature DB >> 26410751

Motor onset and diagnosis in Huntington disease using the diagnostic confidence level.

Dawei Liu1,2, Jeffrey D Long1,3, Ying Zhang4, Lynn A Raymond5, Karen Marder6,7, Anne Rosser8,9, Elizabeth A McCusker10, James A Mills1, Jane S Paulsen11,12,13.   

Abstract

Huntington disease (HD) is a neurodegenerative disorder characterized by motor dysfunction, cognitive deterioration, and psychiatric symptoms, with progressive motor impairments being a prominent feature. The primary objectives of this study are to delineate the disease course of motor function in HD, to provide estimates of the onset of motor impairments and motor diagnosis, and to examine the effects of genetic and demographic variables on the progression of motor impairments. Data from an international multisite, longitudinal observational study of 905 prodromal HD participants with cytosine-adenine-guanine (CAG) repeats of at least 36 and with at least two visits during the followup period from 2001 to 2012 was examined for changes in the diagnostic confidence level from the Unified Huntington's Disease Rating Scale. HD progression from unimpaired to impaired motor function, as well as the progression from motor impairment to diagnosis, was associated with the linear effect of age and CAG repeat length. Specifically, for every 1-year increase in age, the risk of transition in diagnostic confidence level increased by 11% (95% CI 7-15%) and for one repeat length increase in CAG, the risk of transition in diagnostic confidence level increased by 47% (95% CI 27-69%). Findings show that CAG repeat length and age increased the likelihood of the first onset of motor impairment as well as the age at diagnosis. Results suggest that more accurate estimates of HD onset age can be obtained by incorporating the current status of diagnostic confidence level into predictive models.

Entities:  

Keywords:  Diagnosis; Diagnostic confidence level; Hidden Markov model; Huntington disease; Onset; Prediction

Mesh:

Year:  2015        PMID: 26410751      PMCID: PMC4666501          DOI: 10.1007/s00415-015-7900-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

1.  Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease.

Authors:  T M Blekher; R D Yee; S C Kirkwood; A M Hake; J C Stout; M R Weaver; T M Foroud
Journal:  Vision Res       Date:  2004-10       Impact factor: 1.886

2.  Large normal and reduced penetrance alleles in Huntington disease: instability in families and frequency at the laboratory, at the clinic and in the population.

Authors:  J Sequeiros; E M Ramos; J Cerqueira; M C Costa; A Sousa; J Pinto-Basto; I Alonso
Journal:  Clin Genet       Date:  2010-10       Impact factor: 4.438

3.  Brain structure in preclinical Huntington's disease.

Authors:  Jane S Paulsen; Vince A Magnotta; Ania E Mikos; Henry L Paulson; Elizabeth Penziner; Nancy C Andreasen; Peg C Nopoulos
Journal:  Biol Psychiatry       Date:  2005-08-22       Impact factor: 13.382

4.  Differences in duration of Huntington's disease based on age at onset.

Authors:  T Foroud; J Gray; J Ivashina; P M Conneally
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

5.  Confidence intervals for predicted age of onset, given the size of (CAG)n repeat, in Huntington's disease.

Authors:  G Lucotte; J C Turpin; O Riess; J T Epplen; I Siedlaczk; F Loirat; S Hazout
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

6.  Family and molecular data for a fine analysis of age at onset in Huntington disease.

Authors:  F Squitieri; G Sabbadini; P Mandich; C Gellera; E Di Maria; E Bellone; B Castellotti; E Nargi; U de Grazia; M Frontali; A Novelletto
Journal:  Am J Med Genet       Date:  2000-12-11

7.  Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals.

Authors:  J B Penney; A B Young; I Shoulson; S Starosta-Rubenstein; S R Snodgrass; J Sanchez-Ramos; M Ramos-Arroyo; F Gomez; G Penchaszadeh; J Alvir
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

8.  Longitudinal evaluation of "presymptomatic" carriers of Huntington's disease.

Authors:  Marie-Noëlle W Witjes-Ané; Bart Mertens; Jeroen P P van Vugt; Anne-Catherine Bachoud-Lévi; Gert-Jan B van Ommen; Raymund A C Roos
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

9.  A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes.

Authors:  J P Warner; L H Barron; D J Brock
Journal:  Mol Cell Probes       Date:  1993-06       Impact factor: 2.365

10.  Dystonia in Huntington's disease: prevalence and clinical characteristics.

Authors:  E D Louis; P Lee; L Quinn; K Marder
Journal:  Mov Disord       Date:  1999-01       Impact factor: 10.338

View more
  6 in total

1.  Regional subcortical shape analysis in premanifest Huntington's disease.

Authors:  Xiaoying Tang; Christopher A Ross; Hans Johnson; Jane S Paulsen; Laurent Younes; Roger L Albin; J Tilak Ratnanather; Michael I Miller
Journal:  Hum Brain Mapp       Date:  2018-10-30       Impact factor: 5.038

2.  It Is Time to Define Huntington's Disease Onset more Clearly.

Authors:  Gustavo L Franklin; Carlos Henrique Ferreira; Hélio A G Teive
Journal:  Mov Disord Clin Pract       Date:  2021-03-08

3.  Predictive testing for Huntington disease over 24 years: Evolution of the profile of the participants and analysis of symptoms.

Authors:  Francis Ramond; Isabelle Quadrio; Laurence Le Vavasseur; Hélène Chaumet; Fabrice Boyer; Muriel Bost; Elisabeth Ollagnon-Roman
Journal:  Mol Genet Genomic Med       Date:  2019-08-22       Impact factor: 2.183

Review 4.  Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal.

Authors:  Aditi Bhat; Harshita Dalvi; Harsha Jain; Nagarjun Rangaraj; Shashi Bala Singh; Saurabh Srivastava
Journal:  Curr Res Pharmacol Drug Discov       Date:  2020-12-31

5.  Alterations in metal homeostasis occur prior to canonical markers in Huntington disease.

Authors:  Anna C Pfalzer; Yan Yan; Hakmook Kang; Melissa Totten; James Silverman; Aaron B Bowman; Keith Erikson; Daniel O Claassen
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

6.  Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks.

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Angela Roberts; Praveen Dayalu; Dana L Hanifan; Jennifer A Miner; Daniel Claassen; Emily Mower Provost
Journal:  Qual Life Res       Date:  2020-08-24       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.